Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04602533
Title Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Michael Hopp
Indications

lung small cell carcinoma

Therapies

Cisplatin + Etoposide

Durvalumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.